Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Jurgen Van Broeck

Tracked across 1 events · 8 articles · First seen Sep 18, 2026 · Last active Sep 18, 2026

Sentiment
5
Attention
2
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 5
Business
mAbxience, a majority-owned company of Fresenius (company) with partial ownership from Insud Pharma, and Novartis — Sandoz announced a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar candidate referencing Hemlibra, indicated for…
Impact: As CEO of mAbxience, Jurgen Van Broeck publicly framed the agreement as recognition of the company's development and manufacturing capabilities and its patient-access strategy.
Sep 18, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Jurgen Van Broeck live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.